Alecensa® (alectinib) – Expanded indication, new warning
November 6, 2017 – Genentech announced the FDA approval of Alecensa (alectinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Download PDF
